Apatinib
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer, Randomized Controlled Study
Trial Timeline
Aug 26, 2021 → Mar 3, 2023
NCT ID
NCT05029453About Apatinib
Apatinib is a approved stage product being developed by Jiangsu Hengrui Medicine for Gastric Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT05029453. Target conditions include Gastric Cancer, Randomized Controlled Study.
What happened to similar drugs?
4 of 20 similar drugs in Gastric Cancer were approved
Approved (4) Terminated (3) Active (14)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05029453 | Approved | UNKNOWN |
| NCT03709953 | Phase 2 | UNKNOWN |
| NCT03457467 | Phase 2 | UNKNOWN |
| NCT03521219 | Phase 2 | UNKNOWN |
| NCT03390062 | Phase 2 | UNKNOWN |
| NCT03403452 | Phase 2 | UNKNOWN |
| NCT03383237 | Phase 2 | UNKNOWN |
| NCT03376737 | Phase 2 | UNKNOWN |
| NCT03251443 | Phase 2 | Completed |
| NCT03190616 | Phase 2 | Completed |
| NCT03163381 | Phase 2 | UNKNOWN |
| NCT03180476 | Phase 2 | Completed |
| NCT03144856 | Phase 2 | UNKNOWN |
| NCT03170310 | Phase 2 | UNKNOWN |
| NCT02764268 | Pre-clinical | Completed |
| NCT02727309 | Phase 1/2 | UNKNOWN |
| NCT02509806 | Phase 2/3 | UNKNOWN |
| NCT02510469 | Phase 2/3 | UNKNOWN |
| NCT01653561 | Phase 2 | Completed |
| NCT01192971 | Phase 2 | Completed |
Competing Products
20 competing products in Gastric Cancer